Peroxisome proliferator-activated receptor α L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis

Journal of Investigative Medicine

Volumn 53, Issue 7, 2005, Pages 353-359

  Verdi, Hasibe ^a   Koytak, Elif Sare ^a   Önder, Oǧuz ^a   Ergül, Ayça Arslan ^a   Cinar, Kubilay ^a   Idilman, Ramazan ^a   Erden, Esra ^a   Bozdayi, Abdurrahman Mithat ^a   Yurdayďin, Cihan ^a   Uzunalimoglu, Özden ^a   Bozkaya, Hakan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Fatty liver; Hepatitis C virus; L162V; Nonalcoholic steatohepatitis; Peroxisome proliferator activated receptor ; Polymorphism

Indexed keywords

LEUCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VALINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS;

HEPATITIS C VIRUS;

EID: 29144460994     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2005.53706     Document Type: Article

References (38)

1. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-6.
2. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
3. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
4. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
5. Younossi ZM. Non-alcoholic fatty liver disease. Curr Gastroenterol Rep 1999;1:57-61.
6. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
7. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-9.
8. Neuschwander-Terri BA, Caldwell S. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
9. Sanyal AJ, Campbell-SargentC, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
10. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001;120:1281-4.
11. Green RM. NASH: hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003;38:14-7.
12. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
13. Rao MS, Reddy JK. Peroxisomal β-oxidation and steatohepatitis. Semin Liver Dis 2001;21:43-55.
14. Younossi ZM, Diehl AM, Ong IP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35:746-52.
15. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
16. Desvergne B, Wahli BW. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-88.
17. Akbiyik F, Ray DM, Bozkaya H, Demirpence E. Ligand and species dependent activation of PPARα. Cell Physiol Biochem 2004;14:269-76.
18. Hashimoto T, Cook WS, Qi C, et al. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000;275:28918-28.
19. Johnson EF, Palmer CN, Griffin KJ, Hsu MH. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB J 1996;10:1241-8.
20. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-22.
21. Reddy JK. Nonalcoholic steatosis and steatohepatitis III. Peroxisomal β-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001;281:G1333-9.
22. Fan CY, Pan J, Usuda N, et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J Biol Chem 1998;273:15639-45.
23. Fan CY, Pan J, Chu R, et al. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol Chem 1996;271:24698-710.
24. Akbiyik F, Cinar K, Demirpence E, et al. Ligand induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver. Eur J Clin Invest 2004;34:429-35.
25. Hashimoto T, Fujita T, Usuda N, et al. Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem 1999;274:19228-36.
26. Flavell DM, Pineda Torra I, Jamshidi Y, et al. Variation in the PPAR alpha gene is associated with altered function in vitro and plasma lipid concentrations in type 11 diabetic subjects. Diabetologia 2000;43:673-80.
27. Vohl MC, Lepage P, Gaudet D, et al. Molecular scanning of the human PPAR alpha gene: association of the L162V mutation with hyperapobetalipoproteinemia. J Lipid Res 2000;41:945-52.
28. Tai ES, Demissie S, Cupples LA, et al. Association between the PPAR alpha L162V polymorphism and plasma lipid levels. The Framingham offspring study. Arterioscler Thromb Vasc Biol 2002;22:805-10.
29. Robitaille J, Brouillette C, Houde A, et al. Association between PPAR alpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004;49:482-9.
30. Evans D, Aberle J, Wendt D, et al. A polymorphism, L162V, in the PPAR alpha gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med 2001;79:198-204.
31. Ramalho F. Hepatitis C viral infection and liver steatosis. Antiviral Res 2003;60:125-7.
32. Hezode C, Roudot-Thoraval F, Zafrani ES, et al. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. Viral Hepat 2004;11:455-8.
33. Bozdayi AM, Aslan N, Bozdayi G, et al. Molecular epidemiology of hepatitis B, C and D viruses. Arch Virol 2004;149:2115-29.
34. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
35. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
36. Gouni-Berthold I, Giannakidou E, Muller-Wieland D, et al. Association between the PPAR alpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in non-diabetic controls. Am Heart J 2004;147:1117-24.
37. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extra-hepatic disease. Gastroenterology 2004;126:586-97.
38. Ratziu V, Trabut JB, Poynard T. Fat, diabetes and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 2004;6:22-9.